You are here » Home » Companies » Company Overview » Colinz Laboratories Ltd

Colinz Laboratories Ltd.

BSE: 531210 Sector: Health care
NSE: N.A. ISIN Code: INE923C01011
BSE LIVE 14:16 | 15 May Stock Is Not Traded.
NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 20.50
PREVIOUS CLOSE 20.00
VOLUME 100
52-Week high 21.85
52-Week low 8.75
P/E 51.25
Mkt Cap.(Rs cr) 9
Buy Price 0.00
Buy Qty 0.00
Sell Price 20.50
Sell Qty 200.00
OPEN 20.50
CLOSE 20.00
VOLUME 100
52-Week high 21.85
52-Week low 8.75
P/E 51.25
Mkt Cap.(Rs cr) 9
Buy Price 0.00
Buy Qty 0.00
Sell Price 20.50
Sell Qty 200.00

Colinz Laboratories Ltd. (COLINZLABS) - Director Report

Company director report

Your Directors have pleasure in presenting their 30th Annual Report togetherwith the Audited Accounts of the Company for the Year ended March 31 2016.

(Rs. in Lacs )
Sr. No. Particulars 2015-16 2014-15
1 Turnover 839.89 821.12
2 Profit before Depreciation Interest & Tax (EBITDA) 54.90 55.81
3 Less : Depreciation 28.18 29.75
4 Profit Before Interest & Tax 26.72 26.06
5 Less : Interest 11.58 11.51
6 Profit Before tax /(Loss) 15.14 14.55
7 Less Provision for
Current Tax 2.75 2.67
Deferred Tax 2.93 2.23
8 Profit After Tax /(Loss) 9.46 9.65
9 Balance brought forward from previous year 74.71 90.94
10 Profit available for appropriation 84.17 100.59
11 Less : Additional depreciation upon revision in useful lives of tangible Assets 0 25.88
12 Balance carried over to Balance Sheet 84.17 74.71
13 Earning per Share (Rs.) 0.21 0.21

OPERATIONAL REVIEW

Gross revenues increased nominally to Rs. 839.89 lacs a growth of around 2.28 %against Rs. 821.12 lacs in the previous year inspite of the drought conditions in themajor market for the Company in Maharashtra. Profit before Interest depreciation andtaxation was Rs. 54.90 lacs against Rs. 55.81 lacs in the previous year. After providingfor interest depreciation and taxation of Rs. 45.44 lacs the net profit of the Companyfor the year under review was placed at Rs. 9.46 Lacs as against Rs. 9.65 lacs in theprevious year.

DIVIDEND

Your Directors are unable to recommend any dividend during the year under reviewconsidering the small surplus available and with a view to conserve funds towards marginmonies.

SHARE CAPITAL

The paid up equity capital as on March 31 2016 was Rs 354.41 lacs. During the yearunder review your Company has not issued any shares including Sweat equity ESOP and/orconvertible debentures.

FINANCE & MATERIAL CHANGES AFFECTING FINANCIAL POSITION OF THE COMPANY

Cash and cash equivalents as on March 31 2016 was at Rs. 161.65 lacs. The companycontinues to focus on judicious management of its working capital receivablesinventories and other working capital parameters were kept under strict check throughcontinuous monitoring. No material changes have occurred and commitments made affectingthe financial position of the Company.

PUBLIC DEPOSITS

Your Company has not accepted any deposits within the meaning of Section 73 of theCompanies Act 2013 and the Companies (Acceptance of Deposits) Rules 2014.

PARTICULARS OF LOANS GUARANTEES OR INVESTMENTS

The company has not given any loans or guarantees covered under the provisions ofsection 186 of the Companies Act 2013.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has an Internal Control System commensurate with the size scale andcomplexity of its operations. The scope and authority of the Internal Audit function isdefined. To maintain its objectivity and independence the Internal Audit function reportsto the Chairman of the Audit Committee of the Board.

The Internal Audit Department monitors and evaluates the efficacy and adequacy ofinternal control system in the Company its compliance with operating systems accountingprocedures and policies at all locations of the Company.

The Audit Committee reviews the adequacy and effectiveness of the internal controlsystem and suggests improvement to strengthen the system. It also reviews the quarterlyinternal Audit Reports.

CORPORATE SOCIAL RESPONSIBILITY INITIATIVES.

Not applicable to the Company.

CONSERVATION OF ENERGY

a) Company ensures that the manufacturing operations are conducted in the mannerwhereby optimum utilization and maximum possible savings of energy is achieved.

b) No specific investment has been made in reduction in energy consumption during theyear under review though a Baby boiler is already in place to generate steam as power incertain operations. However pharmaceutical formulation industry does not consume highpower.

c) As the impact of measures taken for conservation and optimum utilization of energyare not quantitative its impact on cost cannot be stated accurately.

TECHNOLOGY ABSORPTION

Company's products are manufactured by using in-house know how and no outsidetechnology is being used for manufacturing activities. Therefore technology absorption isa continuous process. The Company constantly strives for maintenance and improvement inquality of its products and entire development activities are directed to achieve theaforesaid goal.

FOREIGN EXCHANGE EARNINGS AND OUT-GO

During the period under review there was no foreign exchange earnings or out flow.

DIRECTORS

Director Mr. N. K. Menon (Din No. 01111297) Whole Time Director who retires byrotation and being eligible offers himself for re- appointment. The Directors recommendMr. N. K. Menon for re-appointment.

All independent directors have given declarations that they meet the criteria ofindependence as laid down under section 149(6) of the Companies Act 2013 and clause 49 ofthe Listing Agreement.

Board Evaluation

Pursuant to the provisions of the Companies Act 2013 and Clause 49 of the ListingAgreement the Board has carried out an evaluation of its own performance the directorsindividually as well as the evaluation of the working of its Committees. The manner inwhich the evaluation has been carried out has been explained in the Corporate GovernanceReport.

Nomination & Remuneration Policy

Pursuant to section 178 of the Companies Act 2013 and the rules made thereunder fromtime to time and Regulation 19 of the SEBI Regulations 2015 the Board has reconstitutedthe Nomination & Remuneration Committee. The Nomination & Remuneration Committeeframed a policy for selection and appointment reappointment removal appraisal ofDirectors and Senior Management Personnel and their remuneration.

Meetings of Board of Directors

During the year seven Board Meetings and four Audit Committee Meetings were convenedand held the details of which are given in the Corporate Governance Report. Theintervening gap between the Meetings was within the period prescribed under the CompaniesAct 2013.

Directors' Responsibility Statement

In terms of Section 134 (5) of the Companies Act 2013 the directors would like tostate that:

i) In the preparation of the annual accounts the applicable accounting standards havebeen followed;

ii) The directors have selected such accounting policies and applied them consistentlyand made judgments and estimates that were reasonable and prudent so as to give a true andfair view of the state of affairs of the Company at the end of the financial year31-03-2016 and of the profit or loss of the Company for the year under review;

iii) The directors have taken proper and sufficient care for the maintenance ofadequate accounting records in accordance with the provisions of this Act for safeguardingthe assets of the Company and for preventing and detecting fraud and other irregularities;

iv) The directors have prepared the annual accounts on a going concern basis;

v) The directors had laid down internal financial controls to be followed by thecompany and that such internal financial controls are adequate and were operatingeffectively; and

vi) The directors had devised proper system to ensure compliance with the provisions ofall applicable laws and that such system were adequate and operating effectively.

RELATED PARTY TRANSACTIONS

There are no materially significant related party transactions made by the company withPromoters Key Managerial Personnel or other designated persons which may have potentialconflict with interest of the company at large.

Prior omnibus approval of the Audit Committee has been obtained on an annual basis fortransactions with related parties which are of a foreseeable and repetitive nature. Thetransactions entered into pursuant to the omnibus approval so granted and a statementgiving details of all transactions with related parties are placed before the AuditCommittee for their review on a periodic basis.

SUBSIDIARY COMPANIES

The Company does not have any subsidiary.

CODE OF CONDUCT

The Board of Directors has approved a Code of Conduct which is applicable to theMembers of the Board and all employees in the course of day to day business operations ofthe company. The Company believes in "Zero Tolerance" against briberycorruption and unethical dealing/behaviors of any form and the Board has laid down thedirectives to counter such acts. The code laid down by the Board is known as "Code ofbusiness conduct".

The Code lays down the standard procedure of business conduct which is expected to befollowed by the Directors and the designated employees in their business dealings and inparticular on matters relating to integrity in the work place in business practices andin dealing with stakeholders. The Code gives guidance through examples on the expectedbehavior from an employee in a given situation and the reporting structure.

All the Board Members and the Senior Management personnel have confirmed compliancewith the Code. All Management Staff were given appropriate training in this regard.

VIGIL MECHANISM/WHISTLE BLOWER POLICY

The Company has a Fraud Risk and Management Policy to deal with instances of fraud andmismanagement if any. The FRM Policy ensures that strict confidentiality is maintainedwhilst dealing with concerns and also that no discrimination will be meted out to anyperson for a genuinely raised concern.

The Board of Directors has adopted Whistle Blower Policy. The Whistle Blower Policyaims for conducting the affairs in a fair and transparent manner by adopting higheststandards of professionalism honesty integrity and ethical behavior. All permanentemployees of the Company are covered under the Whistle Blower Policy.

PREVENTION OF INSIDER TRADING

The Company has adopted a Code of Conduct for Prevention of Insider Trading with a viewto regulate trading in securities by the Directors and designated employees of theCompany. The Code requires pre-clearance for dealing in the Company's shares and prohibitsthe purchase or sale of Company shares by the Directors and the designated employees whilein possession of unpublished price sensitive information in relation to the Company andduring the period when the Trading Window is closed. The Board is responsible forimplementation of the Code. All Board of Directors and the designated employees haveconfirmed compliance with the Code.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE ( PREVENTION PROHIBITIONAND REDRESSAL ) ACT2013.

"The Company has in place an Anti Sexual Harassment Policy in line with therequirements of The Sexual Harassment of Women at the Workplace (Prevention Prohibition& Redressal) Act 2013. Internal Complaints Committee (ICC) has been set up to redresscomplaints received regarding sexual harassment. All employees (permanent contractualtemporary trainees) are covered under this policy. The following is a summary of sexualharassment complaints received and disposed off during the year 2015-16.

No of complaints received: • NIL

No of complaints disposed off : Not Applicable-

AUDITORS

The Auditors S. V. Bhat & Co. Chartered Accountants Mumbai retire at theconclusion of the ensuing Annual General Meeting and being eligible offer themselves forre-appointment.

SECRETARIAL AUDIT AND AUDIT REPORT

Pursuant to provisions of section 204 of the Companies Act 2013 and The Companies(Appointment and Remuneration of Managerial Personnel) Rules 2014 the company hasappointed M/s Sanjay Dholakia & Associates (CP No. 1798) a firm of CompanySecretaries in practice to undertake the Secretarial Audit of the Company. The SecretarialAudit report is annexed herewith as "Annexure A".

With regard to the observation made in the said report regarding the non-appointmentof Company Secretary the Board of Directors would like to inform the members that theManaging Director Dr. L. S. Mani is himself a qualified Company Secretary ( ACS No.4622) and he is devoting adequate time to undertake all the secretarial work currently.However the Company is in the process of appointing a Company Secretary.

COST AUDIT

The provision of Cost Audit Report is not applicable to the Company.

EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in form MGT-9 is annexedherewith as "Annexure B". PARTICULARS OF EMPLOYEES:

None of the employees or Whole Time Director/Managing Director is in receipt ofremuneration for the year under review in excess of Rs. 60 Lacs. (Sixty Lacs).

INDUSTRIAL RELATION AND HUMAN RESOURCES

Industrial relation during the period under review remained cordial at all levels. TheCompany has a structured appraisal system based on key result areas. The HR is effectivelyinvolved in nurturing enhancing and retaining talent through job satisfactiondevelopment and training programs etc.

CORPORATE GOVERNANCE AND MANAGEMENT DISCUSSION & ANALYSIS REPORTS

The Corporate Governance and Management Discussion & Analysis Report which form anintegral part of this Report are set out as separate Annexure together with theCertificate from the auditors of the Company regarding compliance with the requirements ofCorporate Governance as stipulated in Clause 49 of the Listing Agreement. KEY MANAGAERALPERSONS:

During the year under review the Company has complied with the provisions of section203 of the Companies Act 2013 which provides for the appointment of Key ManagerialPersonnel details of which are available on the website of the Company.

LISTING FEES

The company has paid Listing fees to BSE for the year 2016-17.

ACKNOWLEDGEMENT

Company and its Directors wish to extend their sincerest thanks to the Members of theCompany Bankers State Government Local Bodies Customers Suppliers Executives Staffand Workers at all levels for their continuous cooperation and assistance.

For and on behalf of the Board of Directors
Mumbai Dr. L. S. Mani
15th July 2016 (Managing Director)
(DIN:00825886)